MedCap AB (OSTO:MCAP) YoY EBITDA Growth: 34.05% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:MCAP MedCap AB OSTO:MCAP
96 GF Score
Price kr533.50
GF Value kr576.67
Valuation Fairly Valued
View Full Analysis

What is MedCap AB YoY EBITDA Growth?

MedCap AB OSTO:MCAP +0.75% 96 YoY EBITDA Growth is 34.05% as of Jun. 2026. GuruFocus rates OSTO:MCAP with a GF Score™ of 96/100 and a GF Value™ of kr576.67 (Fairly Valued).

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. MedCap AB's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 34.05%.

MedCap AB's EBITDA per Share for the three months ended in Jun. 2026 was kr9.94.

MedCap AB YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for MedCap AB's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MedCap AB YoY EBITDA Growth Chart

MedCap AB Annual Data
Trend Apr16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.67 23.87 37.51 16.80 17.30

MedCap AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.69 12.54 70.27 25.19 34.05
OSTO:MCAP
96GF Score
MedCap AB OSTO:MCAP
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MedCap AB YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

MedCap AB's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(30.192-25.74)/ | 25.74 |
=17.30 %

MedCap AB's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(9.937-7.413)/ | 7.413 |
=34.05 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 34.05% mean?
MedCap AB (OSTO:MCAP) has a YoY EBITDA Growth of 34.05% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for MedCap AB and its competitors.
Is MedCap AB's YoY EBITDA Growth too high?
MedCap AB's current YoY EBITDA Growth is 34.05%. Overall, MedCap AB has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does MedCap AB's YoY EBITDA Growth compare to ABT and SYK?
MedCap AB's YoY EBITDA Growth of 34.05% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Devices & Instruments company?
A good YoY EBITDA Growth depends on the Medical Devices & Instruments industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for MedCap AB and its competitors. MedCap AB's current YoY EBITDA Growth is 34.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedCap AB stock overvalued right now?
Based on GuruFocus' analysis, MedCap AB (OSTO:MCAP) is currently considered Fairly Valued. The stock's GF Value™ is kr576.67, compared to a current price of kr533.50 — trading 7.5% below its estimated fair value. The current YoY EBITDA Growth is 34.05%. MedCap AB's overall GF Score™ is 96/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For MedCap AB (OSTO:MCAP), the current YoY EBITDA Growth is 34.05% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MedCap AB (OSTO:MCAP) Overvalued in 2026?

Based on GuruFocus' analysis, MedCap AB stock appears to be undervalued. The current stock price of kr533.50 is trading 7.5% below its estimated GF Value™ of kr576.67. GuruFocus considers MedCap AB to be Fairly Valued.

Key valuation signals for OSTO:MCAP:

  • YoY EBITDA Growth: 34.05%
  • GF Value™: kr576.67 vs. price of kr533.50 (7.5% below fair value)
  • GF Score™: 96/100

No single metric tells the full story. See the OSTO:MCAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MedCap AB Business Description

Other Exchanges MCAPs:UK61MA:Germany
Address Sundbybergsvagen 1, Solna, SWE, 171 73
MedCap AB is a Swedish investment company that acquires and develops profitable, market-leading niche businesses in the Nordic life science sector. It operates through two business areas: Medical Technology and Specialist Medicines. The Medical Technology segment develops and sells medical technology products and services, while the Specialist Medicines segment develops and sells pharmaceuticals across the regulatory classes of registered, extemporaneous, and licensed medicines. Its subsidiaries serve healthcare providers, clinics, pharmacies, and patients, primarily in Sweden and other Nordic markets. MedCap generally takes controlling or significant ownership stakes in its portfolio companies and supports their long-term growth, often holding investments for extended periods. Revenue is generated through the consolidated sales of its operating subsidiaries rather than through a single product line, giving the company diversified exposure across medical devices, services, and pharmaceutical distribution and development within the Nordic life science industry.
96GF Score

Get the complete analysis for OSTO:MCAP

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr533.50
Price
kr576.67
GF Value